| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 280, Issue 27, 25383-25387, July 8, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Department of Medical
Biosciences/Physiological Chemistry, Umeå University, SE-901 87
Umeå, Sweden, the Department of Gene
Technology, Tallinn Technical University, Tallinn 12618, Estonia, and the¶
Lipid Biology in Health and Disease Research
Group, Children's Hospital Oakland Research Institute, Oakland, California
94609
Received for publication, February 10, 2005 , and in revised form, May 6, 2005.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
To investigate the relationship between apoA-V and plasma TG levels, Pennacchio et al. (1) examined the correlation between DNA sequence polymorphisms in the apoA-V gene and plasma lipid levels in humans. These authors identified four single nucleotide polymorphisms across and surrounding the human APOAV locus. Analysis of APOAV SNPs in a sample set of 501 random unrelated normolipidemic individuals who had been previously phenotyped for various lipid parameters before and after consumption of high and low fat diets, revealed significant associations between plasma TG levels, VLDL mass, and three of the four SNPs. These SNPs were associated with higher TG levels independent of diet. In further studies, Talmud et al. (4) investigated the effect of variation within the APOC3/A4/A5 gene cluster as a determinant of plasma TG levels, obtaining evidence that variation in the APOAV locus is associated with differences in TGs in healthy men, independent of changes in the APOC3 locus.
Vu-Dac et al. (5)
used human hepatocytes and HepG2 cells to test whether fibrates (TG-lowering
drugs) modulate APOAV gene expression, thereby influencing plasma TG
levels. These investigators found a peroxisome proliferator-activated receptor
(PPAR)
response element in the APOAV promoter. PPAR
agonists strongly up-regulated apoA-V mRNA indicating that the APOAV
gene is a positive and direct target of PPAR activators. In another
report Prieur et al.
(6) reported that the
APOAV promoter possesses farnesoid X-activated receptor elements.
This is particularly interesting because the farnesoid X-activated receptor is
an important regulator of TG levels. Overall, it appears that two nuclear
receptors that regulate TG metabolism, PPAR and farnesoid X-activated
receptor, modulate expression of the APOAV gene.
Although knowledge of apoA-V gene expression is becoming better understood, key questions remain about the mechanism whereby the apoA-V protein influences plasma TG levels. In the present study we evaluated the hypothesis that apoA-V modulates lipoprotein lipase (LPL) activity and demonstrated that apoA-V is a heparin-binding protein. The potential effects of this interaction on metabolism of TG-rich lipoproteins by LPL and lipoprotein receptors are discussed.
|
EXPERIMENTAL PROCEDURES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Other Reagents and Analyses—Heparin was obtained from Novo Nordisk. Biotinylated heparin was prepared by incubation of heparin (5 mg/ml) with a 10-fold molar excess of biotin N-hydroxysuccinimide ester in 0.2 M NaHCO3, pH 8.6. Non-reacted biotin N-hydroxysuccinimide ester was removed by dialysis. Pre- and post-heparin human plasma was taken before and 10 min after injection of 100 units of heparin/kg of body weight to healthy individuals. Blood was collected in heparinized tubes and plasma isolated by centrifugation. Lipids (TG, cholesterol, and phospholipids) were analyzed by enzyme-based colorimetric assay (Wako).
Lipoprotein Lipase Assays—LPL was isolated from bovine milk according to the procedure of Bengtsson-Olivecrona and Olivecrona (8) and stored frozen at a concentration of 0.5–1 mg/ml in 10 mM Bis-Tris buffer, pH 6.5, 1 M NaCl. Prior to use, the enzyme preparation was diluted in 5 mM Na-deoxycholate, 20 mM Tris-Cl, pH 8.5, containing 0.1 mM SDS, a buffer in which LPL activity is well preserved. Three distinct assay systems were employed to analyze the effect of apoA-V on LPL activity. The first employed human VLDL as the substrate at a TG concentration of 1 mg/ml in a total volume of 1 ml in 0.14 M Tris-Cl, pH 7.4, 0.1 M NaCl, 4.5% bovine serum albumin (Sigma, Fraction V) and 0.4 units of heparin/ml (Leo Pharma AB, Malmö, Sweden). ApoA-V, or dilutions thereof, was added in 50 µl of buffer containing 5 M urea. The samples were preincubated for 15–30 min before the addition of LPL, and incubations were carried out for 30 min at 25 °C. Fatty acids released were extracted and determined by manual titration using NaOH (9). The second assay method employed an egg yolk phosphatidylcholine-stabilized emulsion of soybean TG corresponding to Intralipid 10%® (Fresienius-KABI, Uppsala, Sweden) to which a trace amount of [3H]oleic acid-labeled triolein had been incorporated during preparation by the manufacturer. This substrate was used with and without the addition of purified apoC-II or apoC-III1. The system contained 2 mg of TG/ml, 0.15 M Tris-Cl, pH 8.5, 0.1 M NaCl, 6% bovine serum albumin, 0.1 mg of heparin/ml in a total volume of 0.2 ml (10). Apo A-V was added in 10 µl of buffer containing 5 M urea, and apoC-II or apoC-III1 were added in a total of 2 µl of buffer with 5 M urea. Substrates were preincubated 15–30 min prior to the addition of LPL followed by a 15-min incubation at 25 °C. In the absence of apoC-II, 5-fold more LPL was added to achieve an equivalent lipolysis rate. Radiolabeled fatty acids were extracted and counted as described (10). The third system employed liposomes prepared from DMPC but without the addition of radiolabeled DMPC (11). The liposome substrate was preincubated for 1 h at 25°Cata concentration of 1.5 mg of phosphatidylcholine/ml (total volume 1 ml). The phospholipolysis assays were initiated as described above for the TG emulsion substrate, and the released fatty acids were determined by titration (9).
Immunoblotting—Samples were electrophoresed on a 4–20% acrylamide gradient, Tris-glycine SDS gel. Separated proteins were transferred to a 0.2 µm polyvinylidene difluoride membrane at a 150-mAmp constant current for 3 h. Nonspecific binding sites on the membrane were blocked with 0.1% TTBS (0.1% Tween 20, 20 mM Tris, 150 mM NaCl, pH 7.2) overnight at room temperature while rotating. Biotinylated anti-apoA-V IgG was used at a 1:10,000 dilution in 0.1% TTBS. The blot was then washed 0.1% TTBS (4 x 10 min) and incubated with secondary antibody (NeutraAvidin, Pierce) at a dilution of 1:100,000 in TTBS. After washing, the blot was incubated with West Femto Chemiluminescence substrate (Pierce) for 4 min and exposed to x-ray film for 2 min and developed using a M35A X-OMAT processor (Kodak).
Heparin Binding Studies—ApoA-V-DMPC disc particles (7) or apoE3-NT in buffer (20 mM sodium phosphate, pH 7.2) were applied to a 1-ml HiTrap Heparin HP affinity column (Amersham Biosciences). After loading, the column was washed with buffer, and bound proteins were eluted with a linear gradient of NaCl from 0 to 1.0 M.
Surface Plasmon Resonance—Surface plasmon resonance (SPR) binding studies were performed on a BIAcore 2000 (Biacore, Uppsala, Sweden) using CM5 sensor chips (12, 13). Streptavidin was covalently attached to the carboxymethylated surface of the sensor chip activated by N-hydroxysuccinimide and N-(3-diethylaminopropyl)-N'-ethylcarbodiimide. Then biotinylated heparin was bound to the immobilized streptavidin. Binding experiments were carried out at 25 °C in 10 mM HEPES buffer, pH 7.4, containing 0.15 M NaCl and 50 mM guanidine hydrochloride. A stock solution of apoA-V (1.6 mg/ml) was prepared in 6 M guanidine hydrochloride, and dilutions into the running buffer were made just before injection. A solution of 10 mM HEPES, pH 7.4, 1 M NaCl was used for regeneration of the surface of the sensorchips.
Sensorgrams were analyzed with the aid of the BIAevaluation software Version 3 (Biacore, Uppsala, Sweden). To obtain curves of specific binding, background sensorgrams characterizing nonspecific interactions were subtracted from experimental sensorgrams.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Heparin-Sepharose Affinity Chromatography—An examination of the amino acid sequence of mature human apoA-V revealed a stretch of 42 residues that lacks amino acids with negatively charged side chains (residues 186–227). On the other hand, this segment contains 5 Arg and 3 Lys (plus 3 His) residues. Given the strong positive charge density in this region of the protein, we postulated that apoA-V may interact with heparan sulfate proteoglycans. To examine this, apoA-V-DMPC lipid particles were subjected to heparin-Sepharose affinity chromatography (Fig. 2). The results obtained indicated that apoA-V-DMPC lipid particles bind heparin-Sepharose and eluted upon application of a NaCl gradient. ApoA-V-DMPC complexes eluted at 0.36 M NaCl, whereas apoE3-NT, a known heparin-binding protein used as a positive control, eluted at 0.41 M NaCl (not shown).
SPR Spectroscopy—To further explore the interaction of
apoA-V with sulfated glycosaminoglycans, SPR binding experiments were
performed. Fig. 3 shows a
sensorgram of apoA-V binding to a heparin-coated chip. A steady,
time-dependent increase in binding to the heparin-coated surface was observed
that plateaued after 
2600 s, apparently reaching a stable binding state.
Whereas dissociation of bound material was slow, it was rapidly released upon
addition of free heparin. The interaction was characterized by an association
rate constant ka = 4.3 x 104
M–1 s–1 and a dissociation rate
constant kd = 0.009 s–1.
To examine the effect of apoA-V on lipoprotein interactions with the heparin-coated chip, apoC-II-deficient chylomicrons were used (Fig. 4A). In the absence of exogenous apoA-V a small amount of binding was noted. By contrast, prior incubation of the heparin chip with apoA-V caused a significant enhancement in chylomicron binding. Similar results were obtained with VLDL (Fig. 4B), where an even greater enhancement in binding was observed in the presence of apoA-V. On the other hand, apoA-V had little effect on the interaction of HDL with heparin-coated SPR chips (Fig. 4C).
|
|
|
To determine whether a pool of heparan sulfate proteoglycan-bound apoA-V may exist in vivo, blood samples were obtained from subjects prior to and after injection with 100 units of heparin/kg. ApoA-V levels in the pre- and post-heparin treatment plasma samples were examined by immunoblot analysis. The results, shown in Fig. 6, revealed little or no differences in plasma apoA-V concentration as a function of heparin injection.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
|
|
1
µg/ml) suggests it is not merely a structural protein. Schaap et
al. (14) used adenoviral
transfection to increase the levels of apoA-V in mice. These authors found an
apoA-V dose-dependent reduction in postprandial hypertriglyceridemia following
intragastric fat load and concluded that apoA-V stimulates LPL-dependent
clearance of TG-rich lipoproteins. Complementary in vitro experiments
with recombinant apoA-V revealed a >2-fold stimulation of LPL activity. In
other studies, Fruchart-Najib et al.
(15) reported that apoA-V
shifts from HDL to VLDL following a fat load in mice expressing human apoA-V.
These authors also report that enrichment of human VLDL with recombinant
apoA-V induces a 50% increase in LPL activity, leading to the proposal that
apoA-V manifests its biological effects on plasma TG levels by activating LPL.
In the present studies, however, we found no evidence that apoA-V serves as a
direct modulator of LPL activity in vitro. By contrast, apoC-II had a
major stimulatory effect on LPL activity. Importantly, in support of our
findings, Merkel et al.
(16) recently reported that
apoA-V did not affect LPL hydrolysis rates in the absence of proteoglycans.
Thus, although a clear explanation for the different results is not available
at present, it is conceivable that, under certain incubation conditions,
apoA-V may alter the substrate emulsion, thereby increasing TG accessibility
and LPL activity. Further experiments will be required to determine the basis
for the discrepancy between results. Mechanism 2, Intracellular Mode of Action—Based on the unique interfacial properties of apoA-V (17), an intracellular mode of action has been postulated. In studies with transfected COS-1 cells, control proteins including human serum albumin and apoB-6.6 (17), were efficiently secreted during a 3-h radiolabeling period. By contrast, the majority of apoA-V was retained in the cell lysate, with only small amounts recovered in the medium. Immunofluorescence microscopy studies revealed that albumin and apoB-6.6 displayed diffuse endoplasmic reticulum and prominent heminuclear Golgi staining, whereas apoA-V displayed only perinuclear and diffuse cytoplasmic staining, consistent with localization primarily to the endoplasmic reticulum (17). Thus, it is conceivable that apoA-V does not traffic efficiently from the endoplasmic reticulum to the Golgi, resulting in low secretion efficiency. Additional evidence for an intracellular mode of action has been presented by Schaap et al. (14). These authors observed that adenovirus-mediated apoA-V expression in mice decreased the VLDL-TG production rate in a dose-dependent manner. Interestingly, they found no effect on VLDL particle number, suggesting apoA-V impairs lipidation of apoB. When considered in light of the unique interfacial properties of apoA-V (17) the concept that it interferes with nascent lipoprotein secretion efficiency remains viable. This concept is also in keeping with the findings of van der Vliet (18), wherein liver expression of apoA-V was stimulated by partial hepatectomy. In this case, it is conceivable that apoA-V-mediated inhibition of TG secretion preserves this pool of lipid for cellular needs associated with regeneration.
Mechanism 3, Indirect Effect of ApoA-V on Plasma Lipoprotein Metabolism—Possible mechanisms include serving as a ligand for cell surface lipoprotein receptors or facilitation of alternate cell surface interactions. The presence of a stretch of 42 amino acids possessing strong positive charge character in the apoA-V amino acid sequence led us to examine the heparin binding ability of apoA-V. In contrast to the findings of Fruchart-Najib et al. (15), when subjected to heparin-Sepharose affinity chromatography, the binding of apoA-V-DMPC complexes was observed. These studies were followed by SPR characterization of the heparin binding ability of lipoproteins in the presence of apoA-V. The observation that enrichment of a heparin sensor chip with apoA-V induced a significant enhancement in binding of TG-rich lipoproteins suggests that apoA-V can facilitate TG-rich lipoprotein interaction with heparan sulfate proteoglycans in vivo. If so, it may be anticipated that this would increase interaction between LPL and TG-rich lipoprotein substrates, thereby stimulating TG lipolysis with a concomitant reduction of plasma TG levels. Support for this concept was obtained in SPR experiments wherein the heparin-coated chip was preloaded with LPL. Subsequent interaction studies with chylomicrons revealed that prior enrichment with apoA-V results in an increased binding. These studies, which provide direct evidence that ternary interactions between LPL, TG-rich lipoprotein, and heparin are enhanced in the presence of apoA-V, are congruent with the recent findings of Merkel et al. (16) who showed that proteoglycan-bound LPL activity is modulated by apoA-V. Attempts to demonstrate the release of cell surface heparan sulfate proteoglycan-associated apoA-V upon injection of heparin into human volunteers, however, failed to show an affect. It is unclear whether sufficient heparin was infused to release an increment of apoA-V that would be detectable in plasma after 10 min. Interestingly, heparin-induced release of apoA-V from the SPR chips was relatively slow compared with the behavior of LPL (12). It is conceivable that apoA-V-containing lipoprotein interactions with heparan sulfate proteoglycans in vivo are short lived, culminating in lipoprotein particle internalization, as proposed by Mahley and co-workers for apoE-containing lipoproteins (19, 20). A "secretion-capture" hypothesis has been enunciated to explain the role of heparan sulfate proteoglycans in facilitation of apoE-dependent lipoprotein clearance. If such a mechanism exists for apoA-V, pre- and post-heparin plasma samples may not reveal differences in apoA-V levels. At present, it is not known whether apoA-V serves as a ligand for cell surface lipoprotein receptors. Although no precise consensus receptor recognition sequence has been identified for members of the low density lipoprotein receptor family, apoE and apoB binding occurs via concentrated region of high positive charge. Given the presence of such a sequence element in apoA-V, examination of its ability to serve as a ligand for cell surface receptors may reveal new insight.
The evidence presented in this work indicates apoA-V can influence lipoprotein interaction with heparan sulfate proteoglycans. In so doing, it may attract TG-rich lipoproteins to an environment that can either facilitate apoC-II-activated lipolysis by LPL or lipoprotein particle uptake. In either case, the result would be consistent with evidence from apoA-V transgenic and gene-disrupted mice, providing a molecular explanation for the TG-lowering effects of this protein.
|
FOOTNOTES |
|---|
|| To whom correspondence should be addressed. Tel./Fax: 510-450-7645; E-mail: rryan{at}chori.org.
1 The abbreviations used are: apo, apolipoprotein; DMPC,
dimyristoylphosphatidylcholine; LPL, lipoprotein lipase; TG, triglyceride;
VLDL, very low density lipoprotein; PPAR, peroxisome proliferator activated
receptor; SPR, surface plasmon resonance; TTBS; Tris-buffered saline with
Tween.
|
ACKNOWLEDGMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Dorfmeister, W.W. Zeng, A. Dichlberger, S.K. Nilsson, F.G. Schaap, J.A. Hubacek, M. Merkel, J.A. Cooper, A. Lookene, W. Putt, et al. Effects of Six APOA5 Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1866 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Nilsson, S. Christensen, M. K. Raarup, R. O. Ryan, M. S. Nielsen, and G. Olivecrona Endocytosis of Apolipoprotein A-V by Members of the Low Density Lipoprotein Receptor and the Vps10p Domain Receptor Families J. Biol. Chem., September 19, 2008; 283(38): 25920 - 25927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Pullinger, B. E. Aouizerat, I. Movsesyan, V. Durlach, E. J. Sijbrands, K. Nakajima, A. Poon, G. M. Dallinga-Thie, H. Hattori, L. L. Green, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients J. Lipid Res., August 1, 2008; 49(8): 1846 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gerritsen, C. C. van der Hoogt, F. G. Schaap, P. J. Voshol, K. E. Kypreos, N. Maeda, A. K. Groen, L. M. Havekes, P. C. N. Rensen, and K. W. van Dijk ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency J. Lipid Res., May 1, 2008; 49(5): 1048 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nelbach, X. Shu, R. J. Konrad, R. O. Ryan, and T. M. Forte Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice J. Lipid Res., March 1, 2008; 49(3): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dichlberger, L. A. Cogburn, J. Nimpf, and W. J. Schneider Avian apolipoprotein A-V binds to LDL receptor gene family members J. Lipid Res., July 1, 2007; 48(7): 1451 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Qu, G. Perdomo, D. Su, F. M. D'Souza, N. S. Shachter, and H. H. Dong Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice J. Lipid Res., July 1, 2007; 48(7): 1476 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Shu, J. Chan, R. O. Ryan, and T. M. Forte Apolipoprotein A-V association with intracellular lipid droplets J. Lipid Res., July 1, 2007; 48(7): 1445 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Beckstead, K. Wong, V. Gupta, C.-P. L. Wan, V. R. Cook, R. B. Weinberg, P. M. M. Weers, and R. O. Ryan The C Terminus of Apolipoprotein A-V Modulates Lipid-binding Activity J. Biol. Chem., May 25, 2007; 282(21): 15484 - 15489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Schaap, M. C. Nierman, J. F. P. Berbee, H. Hattori, P. J. Talmud, S. F. C. Vaessen, P. C. N. Rensen, R. A. F. M. Chamuleau, J. A. Kuivenhoven, and A. K. Groen Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia J. Lipid Res., October 1, 2006; 47(10): 2333 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. C. Vaessen, F. G. Schaap, J.-A. Kuivenhoven, A. K. Groen, B. A. Hutten, S. M. Boekholdt, H. Hattori, M. S. Sandhu, S. A. Bingham, R. Luben, et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study J. Lipid Res., September 1, 2006; 47(9): 2064 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Spillmann, A. Lookene, and G. Olivecrona Isolation and Characterization of Low Sulfated Heparan Sulfate Sequences with Affinity for Lipoprotein Lipase J. Biol. Chem., August 18, 2006; 281(33): 23405 - 23413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Alborn, M. G. Johnson, M. J. Prince, and R. J. Konrad Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein a5 in human serum. Clin. Chem., March 1, 2006; 52(3): 514 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C.N. Rensen, K. W. van Dijk, and L. M. Havekes Apolipoprotein AV: Low Concentration, High Impact Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2445 - 2447. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
